Bikang Pharmaceutical Xinyi Group Holdings Co., Ltd.

This product is a fluoroquinolone antibacterial drug with a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacteria. It has good antibacterial activity against the following bacteria in vitro: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes and other Enterobacter species, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. Norfloxacin also has antibacterial activity against multi-drug resistant bacteria in vitro. It also has good antibacterial effects on penicillin-resistant Neisseria gonorrhoeae, Haemophilus influenzae and Moraxella catarrhalis. Norfloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

This product is a fluoroquinolone antibacterial drug with a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacteria. It has good antibacterial activity against the following bacteria in vitro: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes and other Enterobacter species, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. Norfloxacin also has antibacterial activity against multi-drug resistant bacteria in vitro. It also has good antibacterial effects on penicillin-resistant Neisseria gonorrhoeae, Haemophilus influenzae and Moraxella catarrhalis. Norfloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

It has a direct inhibitory effect on respiratory syncytial virus (RSV) and a direct inactivation effect on influenza virus A1 and A3. It has no local irritation and in vivo hemolysis. The intravenous injection LD50 of mice is 122.14±41.44mg/kg, the oral gavage LD50 of mice is 147.0g/kg, and the intramuscular injection LD50 is 55g/kg. The maximum tolerance and minimum lethal dose of mice are 48 and 49g/kg respectively. No accumulation effect is observed after six consecutive days of medication.

It has a direct inhibitory effect on respiratory syncytial virus (RSV) and a direct inactivation effect on influenza virus A1 and A3. It has no local irritation and hemolysis in vivo. The LD50 of intravenous injection in mice is 122.14±41.44mg/kg; the LD50 of oral gavage in mice is 147.0g/kg; the LD50 of intramuscular injection is 55g/kg; the maximum tolerance and minimum lethal dose in mice are 48 and 49g/kg respectively. No accumulation effect is observed after six consecutive days of medication.

This product is a second-generation sulfonylurea oral hypoglycemic drug. It can promote the secretion of insulin by pancreatic beta cells and enhance the effect of insulin on target tissues; it can also stimulate pancreatic alpha cells to inhibit the secretion of glucagon, inhibit the decomposition of liver glycogen, and promote muscle utilization and consumption of glucose.

It has anti-cerebral ischemia effect, improves brain edema in rats with multiple cerebral infarction, promotes glial cell reaction of brain softening foci, accelerates the absorption and organization of softening foci, and reduces neuronal lesions in the hippocampus; it has a protective effect on delayed neuronal damage in the hippocampus of gerbils with transient cerebral ischemia, reduces the Ca2 content in brain tissue after ischemia, reduces the number of dead neurons, and increases neuronal density. It has anti-myocardial ischemia effect, can reduce the downward shift of the S-T segment of the electrocardiogram caused by acute myocardial ischemia in rats, and adjust the heterogeneity of the electrocardiogram. It improves blood rheology, reduces whole blood viscosity and plasma viscosity, reduces hematocrit and platelet aggregation rate, slows down erythrocyte sedimentation rate, and reduces fibrinogen content. It improves microcirculation, reduces the microcirculation morphological integral, flow integral, semi-circular integral, and overall integral of the nail fold microcirculation, reduces peri-loop exudation, increases flow velocity, reduces red blood cell aggregation, reduces loop top congestion, increases loop clarity, and subsides edema. It has the effect of lowering blood lipids, reducing total cholesterol, triglycerides, and low-density lipoprotein levels. It has the effect of resisting free radical damage, increasing the activity of superoxide dismutase in erythrocytes, reducing the content of plasma malondialdehyde, and reducing the content of serum protein kinase C and aspartate aminotransferase.